Bayer Signs a License Agreement with Sensible Medical for its ReDS Technology in Europe
Shots:
- Bayer will utilize Sensible’s ReDS technology as a biomarker for monitoring lung congestion in a clinical study for patients with heart failure- making Bayer- Sensible's largest customer in Europe
- The ReDS System is used as Point-of-Care device/marker of lung fluid- producing a Continuum of Care for patients with fluid management problems + HF/ recovering from coronary artery diseases
- The ReDS System is a wearable vest- quantifying the amount of lung fluid non-invasively and has received FDA’s 510 (k) & CE marking- currently being commercialized in the US
Ref: PRNewsWire | Image: Retail Design Blog
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com